Claudin-14 promotes colorectal cancer progression via the PI3K/AKT/mTOR pathway

被引：17

作者：

Qiao, Tian-Yu ^{[1
]}

Yuan, Zi-Ming ^{[1
]}

Ma, Tian-Yi ^{[1
]}

Hu, Han-Qing ^{[1
]}

Zhu, Yi-Hao ^{[1
]}

Zhang, Wei-Yuan ^{[1
]}

Zhang, Qian ^{[1
]}

Huang, Rui ^{[1
]}

Tang, Qing-Chao ^{[1
]}

Wang, Gui-Yu ^{[2
]}

Wang, Xi-Shan ^{[1
,3
]}

机构：

[1] Harbin Med Univ, Dept Colorectal Surg, Affiliated Hosp 2, Harbin, Peoples R China

[2] Univ Chinese Acad Sci, Dept Colorectal Surg, Canc Hosp, Hangzhou, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China

来源：

NEOPLASMA | 2021年 / 68卷 / 05期

关键词：

colorectal cancer; Claudin-14; PI3K/AKT/mTOR pathway; SIGNALING PATHWAY; BIOMARKER; CLDN14;

D O I：

10.4149/neo_2021_210210N203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer is the third leading cancer in the world in terms of incidence and mortality. The role of differentially expressed Claudin-14 (CLDN14) in CRC has not been reported. We observed that CLDN14 was associated with the progression of CRC. Our functional studies have shown that CLDN14 promoted the proliferation of CRC cells. In addition, CLDN14 also increased the migration and invasion of CRC cells. In vivo experiments also showed that CLDN14 promoted the growth of colorectal cancer via the PI3K/AKT/mTOR. In summary, our research suggests that CLDN14 promotes the progression of colorectal cancer. Our findings may provide new strategies for clinical management and patient prognosis of CRC.

引用

页码：947 / +

页数：9

共 50 条

[1] MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway
Wei Su
Baijie Feng
Lina Hu
Xianzhi Guo
Minghua Yu
[J]. BMC Cancer, 22
[2] MUC3A promotes the progression of colorectal cancer through the PI3K/Akt/mTOR pathway
Su, Wei
Feng, Baijie
Hu, Lina
Guo, Xianzhi
Yu, Minghua
[J]. BMC CANCER, 2022, 22 (01)
[3] NUCKS1 promotes the progression of colorectal cancer via activating PI3K/AKT/mTOR signaling pathway
Zhu, Liao-Liao
Shi, Jing-Jie
Guo, Yong-Dong
Yang, Cheng
Wang, Rong-Lin
Li, Shan-Shan
Gan, Dong-Xue
Ma, Pei-Xiang
Li, Jun-Qiang
Su, Hai-Chuan
[J]. NEOPLASMA, 2023, 70 (02) : 272 - 286
[4] Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway
Cheng, Feng-Wu
Peng, Li-Ming
Luo, Dan
[J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (07) : 748 - 758
[5] TMAO promotes dementia progression by mediating the PI3K/Akt/ mTOR pathway
Hu, Xiaojuan
Zhang, Yamin
Gu, Cheng
Wu, Ruipeng
Yao, Yuping
Gao, Fulin
Luo, Lulu
Zhang, Yi
[J]. TISSUE & CELL, 2023, 81
[6] The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer
Dobbin, Zachary C.
Landen, Charles N.
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (04): : 8213 - 8227
[7] Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway
Yin, Feng
Huang, Xiaoxia
Xuan, Yi
[J]. DISEASE MARKERS, 2021, 2021
[8] LHPP suppresses gastric cancer progression via the PI3K/AKT/mTOR signaling pathway
Wang, Danfang
Li, Jianhui
Li, Wenhan
[J]. JOURNAL OF CANCER, 2022, 13 (14): : 3584 - 3592
[9] KIFC3 Promotes Proliferation, Migration, and Invasion in Colorectal Cancer via PI3K/AKT/mTOR Signaling Pathway
Liao, Huiling
Zhang, Lan
Lu, Shimin
Li, Wei
Dong, Weiguo
[J]. FRONTIERS IN GENETICS, 2022, 13
[10] LGR6 promotes the progression of gastric cancer through PI3K/AKT/mTOR pathway
Ke, Jing
Ma, Peng
Chen, Jinpeng
Qin, Jun
Qian, Haixin
[J]. ONCOTARGETS AND THERAPY, 2018, 11 : 3025 - 3033

← 1 2 3 4 5 →